SCHEMBL7920173

SCHEMBL7920173

O=C1CCCCc2c(Br)cccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.53
PARP11 Q9NR21 1/20 0.53
PIM1 P11309 1/20 0.47
CSNK1A1 P48729 1/20 0.47
CDK5 Q00535 1/20 0.47
ROCK1 Q13464 1/20 0.47
DYRK1A Q13627 1/20 0.47
LRRK2 Q5S007 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
DYRK1B Q9Y463 1/20 0.47
KDM4E B2RXH2 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP2A6 P11509 1/20 0.44
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
BRD4 O60885 1/20 0.36
ADRB2 P07550 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30003712 1.00 PARP10 (0.53) PARP10PARP11PIM1CSNK1A1CDK5
SCHEMBL1661783 0.96 PARP10 (0.53) PARP10PARP11PIM1CSNK1A1CDK5
SCHEMBL29514736 0.96 PARP10 (0.53) PARP10PARP11PIM1CSNK1A1CDK5
SCHEMBL28004728 0.89 PARP10 (0.47) PARP10PARP11PIM1CSNK1A1CDK5
SCHEMBL29429928 0.88 PARP10 (0.56) PARP10PARP11PIM1CSNK1A1CDK5
SCHEMBL163925 0.88 PARP10 (0.56) PARP10PARP11PIM1CSNK1A1CDK5
Methylamine SCHEMBL27811293 0.82 PARP10 (0.51) PARP10PARP11PIM1CSNK1A1CDK5
SCHEMBL28041457 0.79 MAOA (0.56) KDM4EHSD17B10CYP2A6MAOAMAOB
SCHEMBL5752790 0.78 PARP1 (0.55) PARP10PARP11KDM4ECYP2A6MAOA
SCHEMBL7052870 0.77 PARP10 (0.58) PARP10PARP11PIM1CSNK1A1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3746064-B1 COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE BRAIN INJURY UNIV COPENHAGEN (DK) 2025-04-16 EP disclosed
US-20240391865-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY OTAGO INNOVATION LIMITED (NZ) 2024-11-28 US disclosed
US-12077495-B2 Compounds for the treatment of acute brain injury Københavns Universitet (DK) 2024-09-03 US disclosed
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF ASIA VISION LIMITED (CN) 2024-07-18 US disclosed
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF ASIA VISION LIMITED (CN) 2024-07-18 US disclosed
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF ASIA VISION LIMITED (CN) 2024-07-18 US disclosed
US-20210122700-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY UNIVERSITY OF OTAGO (NZ) 2021-04-29 US disclosed
EP-3746064-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY Københavns Universitet (DK) 2020-12-09 EP disclosed
EP-2704571-B1 AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK SHARP & DOHME (US) 2020-04-22 EP disclosed
EP-2704571-B1 AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK SHARP & DOHME (US) 2020-04-22 EP disclosed
WO-2012151137-A1 AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-11-08 WO disclosed
WO-2012151137-A1 AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-11-08 WO disclosed
US-20110251207-A1 BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2011-10-13 US disclosed
US-20110251207-A1 BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2011-10-13 US disclosed
WO-2010042473-A1 BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS SCHERING CORPORATION (US) 2010-04-15 WO disclosed
WO-2010042475-A1 SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS SCHERING CORPORATION (US) 2010-04-15 WO disclosed
CN-1110485-C 1-arylsulphonyl, aryl(thio) carbonyl pyridazino derivatives and methods of preparation ORTHO PHARMA CORP (US) 2003-06-04 CN disclosed
CN-1207091-A 1-arylsulphonyl, aryl(thio) carbonyl pyridazino derivatives and methods of preparation ORTHO PHARMA CORP (US) 1999-02-03 CN disclosed
US-5753655-A PROGESTINS OR ANTIPROGESTINS ORTHO PHARMACEUTICAL CORPORATION (US) 1998-05-19 US disclosed
WO-1997017332-A1 1-ARYLSULPHONYL, ARYL(THIO)CARBONYL PYRIDAZINO DERIVATIVES AND METHODS OF PREPARATION ORTHO PHARMACEUTICAL CORPORATION (US) 1997-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12077495-B2 Compounds for the treatment of acute brain injury F2R, F2RL3, ARG2 PARP10 593/4885PARP11 271/4885PIM1 3937/4885
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF BCL2, BCL2L2, BCL2L1 PARP10 1868/4885PARP11 1597/4885PIM1 2995/4885
US-20210122700-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY F2R, F2RL3, ARG2 PARP10 702/4885PARP11 294/4885PIM1 3978/4885
US-20240391865-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY F2R, F2RL3, ARG2 PARP10 702/4885PARP11 294/4885PIM1 3978/4885
US-20110251207-A1 BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS ADRA2C, ADRB2, ADRB3 PARP10 3326/4885PARP11 3038/4885PIM1 4850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.